ISSN 2149-2263 | E-ISSN 2149-2271
pdf
Effects of different statins, ezetimibe/simvastatin combination on hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial [Anatol J Cardiol]
Anatol J Cardiol. 2011; 11(8): 703-710 | DOI: 10.5152/akd.2011.192

Effects of different statins, ezetimibe/simvastatin combination on hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial

Esat Namal1, Nur Şener2, Turgay Ulaş3, Zafer Akçalı1, Erkan Öztekin4, Fatih Borlu5
1Bilim Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji Bilim Dalı, İstanbul
2Kartal Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Bilim Dalı, İstanbul
3Harran Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Şanlıurfa
4Şişli Etfal Eğitim ve Araştırma Hastanesi, Kardiyoloji Anabilim Dalı, İstanbul
5Şişli Etfal Eğitim ve Araştırma Hastanesi, Kardiyoloji Anabilim Dalı, İstanbul-Türkiye

Objective: The aim of our study was to evaluate the effects of two different statins and a statin/ezetimibe combination on high sensitive C-reactive protein (hsCRP) values, which were given at high doses in the early period of acute coronary syndromes. Methods: A total of 150 patients with non-ST elevation myocardial infarction and unstable angina pectoris were enrolled to our prospective, randomized, single-blind study. Patients were divided into three groups by block randomization method. One group received 20mg/day atorvastatin, one group received 10 mg/day rosuvastatin and the other group received 10 mg/day ezetimibe/simvastatin combination therapy, which was initiated within the first 24 hours of admission. Follow-up duration was 2 months. Biochemical investigations and hsCRP levels (by nephelometric method) were performed with 138 patients evaluated at baseline, 10th and 60th days of therapy. Decreases of hsCRP levels were analyzed with one-way MANOVA and repeated measures of ANOVA methods. Post-hoc Tukey HSD test was performed for finding the different group, when the difference was detected between the groups. Results: Tenth day hsCRP levels in ezetimibe/simvastatin group was significantly lower than the other groups (p<0.001). Further, after 60 days of follow-up a significant reduction was seen in hsCRP levels in ezetimib/simvastatin group (in ezetimibe/simvastatin group the mean hsCRP was reduced from 38.4±15.0 mg/L to 2.4±1.3 mg/L, in atorvastatin group the mean hsCRP was reduced from 27.3±11.7 mg/L to 4.1±2.4 mg/L and in rosuvastatin group the mean hsCRP was reduced from 22.0±6.9 mg/L to 3.6±1.7 mg/L (F (1.1, 148.2) = 746.9, p<0.01 and the difference between drugs; F (2.2, 148.2) = 32.1, p<0.01). No side effects related to drugs were seen during follow-up in all three treatment groups. Conclusion: This study showed that ezetimibe/simvastatin 10 mg/day combination treatment was superior to atorvastatin 20 mg/day and rosuvastatin 10 mg/day treatment in reducing the inflammatory markers when high dose statins was started in the early period of unstable angina and non ST elevation myocardial infarction.

Keywords: Acute coronary syndrome, statins, treatment, C - reactive protein, lipids

Esat Namal, Nur Şener, Turgay Ulaş, Zafer Akçalı, Erkan Öztekin, Fatih Borlu. Effects of different statins, ezetimibe/simvastatin combination on hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial. Anatol J Cardiol. 2011; 11(8): 703-710
Manuscript Language: English


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 The Anatolian Journal of Cardiology



Kare Publishing is a subsidiary of Kare Media.